MIR1273A: A Potential Drug Target and Biomarker (G100302165)
MIR1273A: A Potential Drug Target and Biomarker
MIR1273A is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. Its primary function is to regulate the levels of glucose in the body, which is crucial for maintaining proper energy metabolism. MIR1273A has been identified as a potential drug target and biomarker due to its unique structure and its involvement in glucose regulation.
The MIR1273A protein is a member of the MIR family, which includes several related proteins that are involved in the regulation of various physiological processes in the body. The MIR1273A protein is composed of 21 amino acid residues and has a calculated molecular mass of 21.1 kDa. It has a unique structure that consists of a single transmembrane domain and a cytoplasmic tail.
MIR1273A is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is highly expressed in the pancreas, which is responsible for producing insulin to regulate blood glucose levels. MIR1273A is also expressed in the brain, which is responsible for glucose metabolism and the regulation of appetite and energy expenditure.
MIR1273A's unique structure and its involvement in glucose regulation make it an attractive drug target. The transmembrane domain of MIR1273A is thought to play a crucial role in its glucose regulatory function. The domain is involved in the formation of a cation-exchange complex, which is responsible for the regulation of glucose uptake and release from the cell surface. The cytoplasmic tail of MIR1273A is also thought to be involved in its glucose regulatory function.
In addition to its potential drug target properties, MIR1273A has also been identified as a biomarker for various diseases. For example, MIR1273A has been used as a biomarker for non-alcoholic steatohepatitis (NASH), which is a type of liver disease that is characterized by the accumulation of fat in the liver. Studies have shown that MIR1273A is overexpressed in NASH patients and that inhibiting its activity may be a potential therapeutic approach for this disease.
MIR1273A has also been identified as a potential biomarker for other diseases, including cardiovascular disease and cancer. For example, MIR1273A has been shown to be overexpressed in patients with cardiovascular disease and that inhibiting its activity may be a potential therapeutic approach for this disease.
In conclusion, MIR1273A is a protein that is expressed in various tissues of the body and has been identified as a potential drug target and biomarker. Its unique structure and its involvement in glucose regulation make it an attractive target for drug development. Further research is needed to fully understand the role of MIR1273A in glucose regulation and its potential as a drug target and biomarker.
Protein Name: MicroRNA 1273a
More Common Targets
MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539
